Researchers say they have identified the most cost-effective therapies for metastatic hormone-sensitive prostate cancer.
Dr. Ryner Lai is a medical writer who is passionate about the power of medical research and innovation to transform the lives of patients. He received his MBBS in Medicine from Queen Mary University in London.
All articles by Ryner Lai, MBBS
In a phase 3 trial, niraparib maintenance improved progression-free survival in patients with advanced ovarian cancer, regardless of biomarker status or postoperative residual disease.